Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.
Thorvardur Halfdanarson, MD
Advertisement
Articles by Thorvardur Halfdanarson, MD
Thorvardur (Thor) Halfdanarson, MD, discusses investigational agents that are being evaluated in patients with colorectal cancer who do not harbor genomic alterations.
Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.
Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Halfdanarson on Molecular Differences Between Left- Versus Right-Sided Tumors in CRCPublished: August 12th 2020 | Updated:
Dr. Halfdanarson on Investigational Agents in Driver-Negative CRCPublished: September 3rd 2020 | Updated:
Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRCPublished: October 21st 2020 | Updated:
Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRCPublished: September 1st 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
5